• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int Urol Nephrol . Post-COVID-19 outcomes of non-dialysis dependent chronic kidney disease patients: a national, multicenter, controlled study

tetano

Editor, Senior Moderator
Int Urol Nephrol


. 2022 Aug 11.
doi: 10.1007/s11255-022-03329-8. Online ahead of print.
Post-COVID-19 outcomes of non-dialysis dependent chronic kidney disease patients: a national, multicenter, controlled study


Serhat Karadag[SUP] 1 [/SUP], Savas Ozturk[SUP] 2 [/SUP], Mustafa Arici[SUP] 3 [/SUP], Numan Gorgulu[SUP] 4 [/SUP], Esra Akcali[SUP] 5 [/SUP], Irem Pembegul[SUP] 6 [/SUP], Dilek Guven Taymez[SUP] 7 [/SUP], Rumeyza Kazancioglu[SUP] 8 [/SUP], Yavuz Ayar[SUP] 9 [/SUP], Ruya Mutluay[SUP] 10 [/SUP], Arzu Ozdemir[SUP] 11 [/SUP], Zeki Aydin[SUP] 12 [/SUP], Yagmur Bashan[SUP] 1 [/SUP], Selma Alagoz[SUP] 13 [/SUP], Fatih Yilmaz[SUP] 14 [/SUP], Sinan Trabulus[SUP] 15 [/SUP], Ahmet Burak Dirim[SUP] 2 [/SUP], Ilyas Ozturk[SUP] 16 [/SUP], Ayca Inci[SUP] 17 [/SUP], Alper Azak[SUP] 18 [/SUP], Nimet Aktas[SUP] 19 [/SUP], Tolga Kuzu[SUP] 20 [/SUP], Hamad Dheir[SUP] 21 [/SUP], Taner Basturk[SUP] 22 [/SUP], Tuba Elif Ozler[SUP] 23 [/SUP], Mevlut Tamer Dincer[SUP] 4 [/SUP], Kenan Turgutalp[SUP] 5 [/SUP], Sena Ulu[SUP] 24 [/SUP], Ozkan Gungor[SUP] 16 [/SUP], Elif Ari Bakir[SUP] 25 [/SUP], Ali Riza Odabas[SUP] 26 [/SUP], Nurhan Seyahi[SUP] 15 [/SUP], Alaattin Yildiz[SUP] 2 [/SUP], Kenan Ates[SUP] 27 [/SUP]



Affiliations

Abstract

Purpose: Coronavirus disease 2019 (COVID-19) has a higher mortality in the presence of chronic kidney disease (CKD). However, there has not been much research in the literature concerning the outcomes of CKD patients in the post-COVID-19 period. We aimed to investigate the outcomes of CKD patients not receiving renal replacement therapy.
Methods: In this multicenter observational study, we included CKD patients with a GFR < 60 ml/min/1.73 m[SUP]2[/SUP] who survived after confirmed COVID-19. Patients with CKD whose kidney disease was due to diabetic nephropathy, polycystic kidney disease and glomerulonephritis were not included in this study. CKD patients with similar characteristics, who did not have COVID-19 were included as the control group.
Results: There were 173 patients in the COVID-19 group and 207 patients in the control group. Most patients (72.8%) were treated as inpatient in the COVID-19 group (intensive care unit hospitalization: 16.7%, acute kidney injury: 54.8%, needing dialysis: 7.9%). While there was no significant difference between the baseline creatinine values of the COVID-19 group and the control group (1.86 and 1.9, p = 0.978, respectively), on the 1st month, creatinine values were significantly higher in the COVID-19 group (2.09 and 1.8, respectively, p = 0.028). Respiratory system symptoms were more common in COVID-19 patients compared to the control group in the 1st month and 3rd month follow-ups (p < 0.001). Mortality at 3 months after the diagnosis of COVID-19 was significantly higher in the COVID-19 group than in the control group (respectively; 5.2% and 1.4%, p:0.037). Similarly, the rate of patients requiring dialysis for COVID-19 was significantly higher than the control group (respectively; 8.1% and 3.4%, p: 0.045).
Conclusions: In CKD patients, COVID-19 was associated with increased mortality, as well as more deterioration in kidney function and higher need for dialysis in the post-COVID-19 period. These patients also had higher rate of ongoing respiratory symptoms after COVID-19.

Keywords: CKD; COVID-19; Outcomes.
 
Back
Top Bottom